Group 1 - Diamond Hill Capital's "Small Cap Strategy" reported a 7.93% return in Q3 2025, underperforming the Russell 2000 Index which gained over 12% [1] - The underperformance was attributed to the rally being driven by sectors not typically held in the portfolio [1] - Centrus Energy Corp. (NYSEAMERICAN:LEU) experienced a one-month return of -34.95% but a 52-week gain of 208.18%, closing at $254.22 with a market cap of $4.63 billion [2] Group 2 - Centrus Energy Corp. was highlighted as a top contributor in Q3, benefiting from renewed interest in nuclear power due to rising power demand linked to the AI boom [3] - The company is positioned well as a nuclear fuel broker with growing enrichment capabilities, supporting U.S. energy independence [3] - Centrus Energy Corp. was held by 27 hedge fund portfolios at the end of Q2 2025, an increase from 23 in the previous quarter [4]

After Centrus Energy ( LEU ) published its Q3 results, I re-analyzed it with the same doubt that I see in part of the market and whether it should be valued as a traditional industrial company orI’m an economist and independent investor from Argentina. I focus on connecting macroeconomic dynamics with company-level valuation to identify long-term opportunities. Living in Argentina gives me a firsthand view of one of the most complex and dynamic markets, which allows me to cover local assets in depth while a ...

Core Insights - The demand for nuclear energy is increasing due to the growth of the AI-driven economy, highlighting a renewed interest in nuclear energy sources [1] - Centrus Energy has experienced significant stock volatility but remains a strong performer in the uranium sector, with a year-to-date increase of over 340% [2][8] Company Performance - Centrus reported Q3 sales of $74.9 million, a 30% increase year-over-year, but fell short of analyst expectations by approximately $5 million [6] - The company achieved a GAAP EPS of $0.19, exceeding expectations but down nearly 90% from Q2 [7] - Centrus has a market cap of around $5 billion and is currently facing a 23% short interest, indicating skepticism in the market [8] Market Demand - There is a strong demand for U.S.-owned enrichment capacity, with traditional utilities expanding nuclear capacity and technology companies investing in nuclear energy for data centers [5] - Analysts project Centrus will generate $451 million in revenue for FY 2025, with a P/S ratio of 11, placing it in the 98th percentile for the past decade [10] Future Projections - Analysts expect Centrus's sales to rise to $855 million by 2030, which would lower the P/S ratio to 6x [11] - EPS is projected to reach $4.96 for FY 2025, with a long-term estimate of $16.80 for 2030, indicating a potential P/E of 17x [11] - If Centrus can achieve a CAGR of 30% in EPS growth, the stock could reach around $500 per share, representing a 75% upside from current levels [13] Strategic Developments - Centrus has appointed a new CFO, completed an $800 million convertible debt offering, and ended Q3 with $1.6 billion in unrestricted cash, positioning itself for future growth [12]

The West’s top nuclear fuelmaker is doubling the size of a planned expansion in the Netherlands, as pressure increases on US and European utilities to phase out Russia-enriched uranium https://t.co/AuKKhYtvum ...

Urenco USA, the only US supplier of nuclear fuel for conventional reactors, has received permission from regulators to make a new type of uranium fuel https://t.co/bVgCz86ouy ...

Company Operations - Centrus Energy 拥有一座先进核燃料生产设施，该设施设计运行 11,000 台离心机[1] - 目前只有 16 台离心机在运行，因为该公司正在等待市场需求的出现[1]

Equity Raising Overview - Silex is undertaking an equity raising of up to $130 million through a placement to eligible investors[11] - A share purchase plan (SPP) to eligible shareholders in Australia and New Zealand aims to raise up to $15 million[11] - The placement price is fixed at $3.90 per share, representing a 15.8% discount to the last close of $4.63 per share[42] and a 10.5% discount to the 5-day VWAP of $4.36 per share[42] - SPP shares will be issued at the lower of the placement price and a 2% discount to the 5-day VWAP up to the SPP closing date[42] Use of Proceeds - The proceeds from the offer, along with existing cash of approximately $69.6 million, will primarily support GLE's commercialization of the SILEX uranium enrichment technology in the US[41, 42] - Funds will also be used to pursue Silex's additional isotope production opportunities and strengthen the company's balance sheet[41, 42] - Silex expects to be fully funded through to the end of FY2028 following the placement[42] GLE Commercialization and Opportunities - GLE aims for commercial deployment of the SILEX uranium enrichment technology by 2030[40] - GLE's strategy includes potential production of UF6, LEU/LEU+, and HALEU at the Paducah Laser Enrichment Facility (PLEF)[41] - GLE has exclusive access to valuable uranium tails inventories from the US DOE, potentially producing up to 5 million lbs p a of natural grade uranium (as UF6) for up to 30 years[41, 74, 85]